Indena, Thorne Research Forge Partnership

MILAN, ITALYIndena SpA and Throne Research, Inc. , have announced a strategic partnership involving research, commercial and scientific cooperation that is intended to result in clinically validated botanical ingredients for dietary supplements to be manufactured and marketed exclusively by Thorne to licensed health-care practitioners. Also, under terms of the agreement, Idb Holding, Indenas parent company, will gain a minority stake in Thorne Holding, the investment arm of Thorne Research. 

The companies plan to focus their product development collaboration on specific health needs such as cancer support and diabetes, while still supporting Thornes established alliances with Helsinn Pharmaceuticals and Integrative Health Resources.  .  Indena will also become a contributing partner to the medical portal Healthelements.com for both product quality assessment programs, and safety and activity related information.

Indena welcomes this strategic cooperation with Thorne Research, a company that shares our commitment to excellence, quality and purity in the development of dietary supplements, said  Daniele Giavini, general manager of Indena, adding Thorne has 25 years of experience developing and marketing a wide range of supplements that reflect the industrys highest standards in safety and efficacy. Through this collaboration we will work to develop a new generation of high-quality supplements with remarkable safety and efficacy profiles that will help people improve their health and quality of life.

This collaboration represents a major advance in Thornes ongoing commitment to providing the finest nutritional supplements and health products to clinicians and patients, said Paul Jacobson, CEO of Thorne Research. Indena shares our commitment to improving health, and we expect that this effort will lead to many important advances in supplements based on botanicals and other nutritional products in diverse areas of health including cancer support, diabetes, cardiovascular disease and nervous system disorders in the years ahead.